Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CEST

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum(TM) (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum(TM) MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum(TM) MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt(®)

For full U.S. Prescribing Information for Fanapt(®), including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
04/23VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
AQ
04/18VANDA PHARMACEUTICALS : to Announce First Quarter 2018 Financial Results on May ..
PR
04/13VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
04/13VANDA PHARMACEUTICALS : Wins Appeal Case on Fanapt®
PR
04/09VANDA PHARMACEUTICALS : to Present Tradipitant Scientific Posters at the 10th Ge..
PR
03/26VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Other Events
AQ
03/26VANDA PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
03/21VANDA PHARMACEUTICALS INC. : Prices Public Offering of Common Stock
AQ
03/19VANDA PHARMACEUTICALS INC. : Proposes Public Offering of Common Stock
AQ
03/16VANDA PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Other E..
AQ
More news
News from SeekingAlpha
03/26Vanda receives notice of Teva application for generic Hetlioz 
03/17YOUR DAILY PHARMA SCOOP : Aratana Earnings, Vanda Offering, Opko 4kscore Shows B.. 
03/16HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (3/16/2018) 
03/16Key events next week - healthcare 
03/16Vanda prices stock offering at $17